26

CStone PharmaceuticalsHKG 2616 Stock Report

Last reporting period 31 Dec, 2023

Updated 19 Sep, 2024

Last price

Market cap $B

0.25

Micro

Exchange

XHKG - Hong Kong Exchange

2616.HK Stock Analysis

26

Uncovered

CStone Pharmaceuticals is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-19/100

Low score

Market cap $B

0.25

Dividend yield

Shares outstanding

1 277.2 B

Cstone Pharmaceuticals Co. Ltd. is an investment holding company, which engages in the research and development of complex biopharmaceutical products and sale of pharmaceutical products. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.

View Section: Eyestock Rating